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Abstract
Objective: The paper projects the contribution to 2011–2015 international targets of three major pandemics by programs in
140 countries funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria, the largest external financier of
tuberculosis and malaria programs and a major external funder of HIV programs in low and middle income countries.
Design: Estimates, using past trends, for the period 2011–2015 of the number of persons receiving antiretroviral (ARV)
treatment, tuberculosis case detection using the internationally approved DOTS strategy, and insecticide-treated nets (ITNs)
to be delivered by programs in low and middle income countries supported by the Global Fund compared to international
targets established by UNAIDS, Stop TB Partnership, Roll Back Malaria Partnership and the World Health Organisation.
Results: Global Fund-supported programs are projected to provide ARV treatment to 5.5–5.8 million people, providing
30%–31% of the 2015 international target. Investments in tuberculosis and malaria control will enable reaching in 2015
60%–63% of the international target for tuberculosis case detection and 30%–35% of the ITN distribution target in sub-
Saharan Africa.
Conclusion: Global Fund investments will substantially contribute to the achievement by 2015 of international targets for
HIV, TB and malaria. However, additional large scale international and domestic financing is needed if these targets are to be
reached by 2015.
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Introduction
In 2000, at the United Nations Millennium Summit the
international community committed to achieving the Millennium
Development Goals (MDGs) [1] including Goal 4 on reducing
child mortality, Goal 5 on improving maternal health and Goal 6
to combat HIV/AIDS, malaria and other communicable diseases
such as tuberculosis (TB) with targets for each aimed at addressing
the huge burden of disease, which in 2008 led to 2 million (1.7–2.4
million) AIDS deaths [2], 1,318,108 (1,087,802–1,672,447) deaths
due to TB [3], and 863,000 (708,000–1,003,000) malaria deaths
[4]. These three pandemics account for the majority of morbidity
and mortality in low-income countries leading to substantial
human suffering and economic loss. In 2005 governments also
committed to ‘‘Developing and implementing a package for HIV
prevention, treatment and care with the aim of coming as close as
possible to the goal of universal access to treatment by 2010 for all
those who need it’’ [5].
These commitments have prompted governments, development
agencies, new financing institutions such as the Global Fund to
Fight AIDS, Tuberculosis and Malaria (the Global Fund),
technical organizations, and the civil society to massively scale
up investments and life-saving and preventive interventions for
addressing these epidemics. These efforts have enabled low- and
middle-income countries to expand the number of people
receiving antiretroviral (ARV) treatment from 300,000 in 2002
to 5.25 million by the end of 2009 [6]; increase in the number of
long lasting insecticidal nets (LLINs) distributed in 35 high-burden
African countries from less than 10 million in 2004 to 35–44
million per year between 2006–2008 [4]; and boost the detection
rate of new smear-positive tuberculosis cases from 40% (36%–
44%) in 2000 to 61% (55%–67%) in 2008 [3].
In spite of these achievements, according to reviews by UN
organizations of progress towards the MDGs [7] and other
internationally agreed targets [8], the scale-up is not sufficient to
meet them (See Box S1 for the targets). However, these reviews did
not utilise the latest available information on investment and scale
up of service delivery interventions [9]. Hence, an up to date
assessment of progress in relation to service delivery targets is
timely.
This paper examines the expected contribution to 2011–2015
international targets of three key service delivery indicators,
namely, people receiving antiretroviral treatment, new smear-
positive TB cases detected and treated under DOTS, and ITNs
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income countries financially supported by the Global Fund.
The Global Fund, an independent international financing
institution, was established in 2002 to invest in low- and middle-
income countries to rapidly scale up interventions to address
AIDS, tuberculosis and malaria epidemics.
In 2008, its share in external global financing amounted to 57%
for tuberculosis control and 60% for malaria. In 2007, that for
HIV was 23% [10]. Between 2003 and 2010, the institution had
disbursed US$13 billion to 140 low- and middle- income
countries. Of this, around 61% was allocated to HIV/AIDS,
24% to malaria and 15% to TB.
Earlier analyses of achievements of the programmatic targets of
country programs supported by the Global Fund indicated limited
contribution relative to internationally agreed targets [10,11].
However, these analyses predate the substantial scale up of these
programs to increase coverage. New data enables reassessment of
the contribution of the programs supported by the Global Fund to
meet international targets.
Methods
Programmatic targets of Global Fund-supported
programs
The two sources of programmatic targets of Global Fund-
supported programs are performance frameworks of approved
proposals. Following negotiation between Global Fund and the
principal grant recipient, these are translated into grant agree-
ments with principal grant recipients in countries for a period of
five years for implementation in two phases (see Box S2 on target
setting, [12]): Phase 1, for two years, and Phase 2, typically for
three years. Targets from performance frameworks are used to
assess the program performance and provision of continued
funding. A detailed performance review at the end of Phase 1 of
implementation against the Phase 1 targets agreed at grant signing
determines whether funding is provided for Phase 2, the scale of
financing provided and the targets to be reached in this phase by
the country program supported by the Global Fund.
With targets of on-going grants changing prior phase 2 and new
round of proposals are continuously increasing the targets of the
entire portfolio, for this paper we project future programmatic
targets of Global Fund-supported programs based on past
performance. We constructed two scenarios to quantify the targets
for the period 2011–2015:
1. Scenario A: for 2011–15 we assumed an annual increase in
targets similar to the average annual increase from 2007 to
2010. The data for this period consists of actual results
achieved (2007–10). After rounding, this scenario projects
annual increases of 560,000 persons receiving ARV treatment,
1.425 million smear-positive tuberculosis cases detected and
treated, and 36 million insecticide treated nets distributed.
2. Scenario B: While scenario A includes a relatively long period
of four years, it consists of investment and scale up patterns that
may not be realised. Therefore, in scenario B we averaged the
actual increases achieved in 2007–08 or increases in 2009–10,
depending on the indicator. In Scenario B, for number of
persons receiving ARVs we averaged the annual increase
achieved in the period 2009–10, which was lower than that
achieved in 2007–8 (as an increasing number of countries begin
to assume domestic financing of ARV treatment). For DOTS,
we averaged the increase in the number of cases during 2009–
10; a figure which was higher than that achieved during 2007–
08. For ITNs we took the average annual increase in 2007–08,
which is lower than the scale-up achieved in 2009–10. The
figures for Scenario B were translated to annual increments of
500,000 ARV treatments, 1.55 million smear-positive tuber-
culosis cases detected and distribution of 26 million ITNs.
The projections are based on past trends and assume no
increase in the scale of funding, in line with the projected financing
for the period in question.
The programmatic targets for smear-positive tuberculosis case
detection are presented as cumulative figures. The programmatic
ITN distribution targets by Global Fund-supported programs are
presented as cumulative figures, but when compared to interna-
tional targets (described below), we assume a fixed life of 4 years
for each net [13]. The ARV targets reflect the number of people
currently receiving ARVs [14].
Results reported by programs
Past results (2005–10) of Global Fund-supported programs
reported by the end of 2010 were compared with international
targets. Grantees are required to periodically report to the Global
Fund their progress against targets and in delivering health
services. Following external review of the data quality of these
programmatic results, they are compared with the programmatic
targets within the performance framework and used to inform
performance-based funding decisions [15]. Programmatic results
relate to people reached with goods and services; e.g. the number
of people receiving ARVs, the number of new smear-positive TB
cases detected under the DOTS strategy, and the number of ITNs
distributed [16]. This allows the Global Fund Secretariat to
aggregate results on the major indicators (the progress reports
submitted by grant recipients are available at http://www.
theglobalfund.org). Some programs report national figures rather
than that specifically for grants, as the Global Fund, in line with
aid effectiveness principles articulated in the 2005 Paris [17],
supports country programs, in many countries providing signifi-
cant proportion of program funding [10]. In particular, for ARV
treatment national figures are used for programs operating at
national scale, that are performing well, where data quality is high,
and where Global Fund financing significantly contribute to the
national efforts. ARV figures are verified with the major agencies,
such as the President’s Emergency Plan for AIDS Relief (PEPFAR)
and WHO, to ensure consistency of measurement and to prevent
double counting in jointly supported programs [18] that provided
ARV treatment to 3.7 million of the 5.25 million people treated
with ARVs in low- and middle-income countries by the end of
2009. Around 1.3 million persons received ARV treatment
through programs jointly financed by these two agencies [6].
The international targets for ARV treatment, case detection of
smear-positive tuberculosis cases and ITN distribution were based
respectively on the targets set by UNAIDS, Stop TB Partnerships,
the Roll Back Malaria Partnership and WHO. The methodologies
used are detailed in Box S1.
Results
ARV treatment targets
Collectively, the Global Fund-supported programs are projected to
almost doublethe current number of peopleon ARVs, from 3 million
a tt h ee n do f2 0 1 0t o5 . 8m i l l i o nb y2 0 1 5i fS c e n a r i oA( t h er a t eo f
increase matches that in 2007–10) continues (Figure 1). In Scenario B
the pace of increase will be slower, reaching 5.5 million people on
ARVs. This is still below the universal access target, which
corresponds to 18.6 million people receiving ARVs by 2015. We
project that the contribution of Global Fund-supported programs to
Scaling Up Towards International Targets
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37% to 31% in Scenario A and to 30% in Scenario B.
TB case detection targets
Between mid-2004 and end-2010, 7.7 million new smear-positive
tuberculosis casesweredetectedandtreatedbyGlobalFund-supported
programs. This accounted for 53% of the international target of 14.7
million new sputum smear-positive cases between mid-2004 and end-
2010: marking a substantial increase from a contribution of 26%
between mid-2004 and end-2005, as shown in Figure 2. Our estimates
suggest that cumulatively by 2015 under Scenario A, the Global Fund-
supported programs will reach 14.85 million people with new smear-
positive TB cases detected and in Scenario B 15.5 million people. As
the international target per annum remains largely unchanged
from 2007 to 2015 while Global Fund-supported programs increase
their annual numbers of new sputum smear-positive TB cases, the
contribution of Global Fund-supported targets is expected to increase
from 53% in 2010 to 60% in Scenario A and 63% in Scenario B of
the international target of 24.6 million new sputum smear-positive TB
cases to be treated between mid-2004 and 2015.
ITN distribution targets
To prevent malaria, by end-2010, Global Fund-supported
programs had distributed 160 million ITNs to people at risk. In
Scenario A, 340 million ITNs will be distributed by 2015, while in
Scenario B this figure will be 290 million (Figure 3). International
targets for ITNs refer to that for sub-Saharan Africa where, as of
2010, around 160 million most-at-risk people (children under-5
and pregnant women) resided in malaria-endemic areas. Achiev-
ing Roll Back Malaria Partnership Global Strategic Plan 2005–
2015 target of 80% coverage (assuming one ITN needed per
person) in 2010 meant distributing 128 million ITNs.
As detailed in Box S1, from 2011 Global Fund-supported
programs will aim to achieve WHO recommendation in 2007
stipulating that all people (not just those at most risk, namely
pregnantwomenandchildrenundertheage offive)inriskareas will
be covered by ITNs in sub-Saharan Africa, accounting for 402
million ITNs by 2015 [19]. The number of ITNs distributed by
Global Fund-supported programs in sub-Saharan Africa increased
ten-fold from 5.1 million in 2005 (5% of the international target) to
105 million in 2010 (82%). By 2015, under Scenario A, the number
of ITNs delivered in sub-Saharan Africa will increase to 246 million
and under Scenario B to 221 million. By 2015, 142 million and 122
million ITNswill stillbe usable (asthey arewithintheir4-yearuseful
life) under scenarios A and B, contributing respectively to 30% and
35% to the targets for sub-Saharan Africa (Figure 4).
Discussion
Global Fund-supported programs have rapidly scaled up HIV,
TB and malaria services enabling an increase in the number of
Figure 1. Results and projected targets of ARV treatment by Global Fund-supported programs, 2005 to 2015. Increase in number of
people provided with ARV treatment through Global Fund-supported program will be slower than the increase in the need, resulting in a slight
decline in their contribution to the international target.
doi:10.1371/journal.pone.0017166.g001
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supported programs, 2005 to 2015. With the increase in number of TB cases detected and treated through Global Fund-supported programs,
these programs are expected to contribute to 60%–63% of the international target.
doi:10.1371/journal.pone.0017166.g002
Figure 3. Results and projected targets of ITN distribution by Global Fund-supported programs, 2005 to 2015. Global Fund-supported
programs are expected to distribute 290–340 million ITNs between 2003 and 2015.
doi:10.1371/journal.pone.0017166.g003
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representing 29% of the global results of 1.3 million people on
ARVs, to 3 million persons by the end of 2010, representing 37%
of the 2010 international targets [11]. However, the increase in
targets for reaching universal access targets by 2015 means the
Global Fund contribution will decline in Scenario B to 30% and in
Scenario A to 31%, requiring substantial increase in domestic and
external financing if the targets are to be reached [20] especially as
the number of people receiving 2
nd line ARVs will increase with
increased longevity.
Reaching universal access targets will require a substantial scale-
up of comprehensive responses that include prevention, testing,
treatment and care [21,22], even though in some settings the HIV
epidemic appears to be stabilizing [2,23,24,25]. Although more
correct data has meant a downward revision of HIV estimates
[26], addressing the HIV epidemic will require more resources
than currently available from international and domestic sources.
The resource needs estimated by UNAIDS amount to US$28.4
billion (range US$21.5–34.6 billion) in 2010 and US$49.5 billion
(range US$40.9–58.1 billion) in 2015, while the cost of reaching
universal access would require US$42.2 billion (US$31.9–51.4
billion) in 2010 and US$54 billion (US$44.6–63.3 billion) in 2015
[27].
The financing of TB control programs in low- and middle-
income countries from the Global Fund has substantially increased
in recent years, globally the TB prevalence and death rates
declining on track to achieve the 2015 targets with the exception of
African countries with a high prevalence of HIV [3].
The full implementation of the Global Plan to Stop TB in sub-
Saharan Africa and the 22 high-burden TB countries between
2006 and 2015 would result in approximately 14 million lives
saved from TB [28]. In sub-Saharan Africa, implementation of the
Plan would translate to US$88.1 billion in economic benefits over
the same time (compared to no increase in the smear-positive case
detection rate from that in 2005). This benefit is almost 9 times
higher than the cost of scale-up estimated by the World Bank to be
US$10 billion [29].
Global Fund-supported programs were able to distribute 142
million ITNs between 2007 and 2010, compared to 18 million in
the period 2002–06. In spite of the scale-up to date and the
proposed expansion of Global Fund-supported malaria programs
the WHO recommendation for providing ITN coverage to the
entire population at risk are not reachable with the current
financing levels. Scaling up ITN distribution must be accompanied
by behavioral change communications to ensure appropriate and
regular use, as owning a bed-net does not readily translate to
correct use [30]. On average, correct ITN use at community
coverage levels of 60% results in a 50% reduction of uncompli-
cated malaria episodes and a decline of 5.5 deaths per 1000
children per year in malaria-endemic sub-Saharan Africa [31].
Rapid scale up in ITN distribution will need to be accompanied by
health systems strengthening to deliver prevention and treatment
Figure 4. Unexpired ITNs distributed by Global Fund-supported programs in sub-Saharan Africa, 2005 to 2015. In 2010 Global Fund-
supported programs have provided over 80% of the international target of ITNs of sub-Saharan Africa. This contribution will reduce to 30%–35% in
2015 with the expansion of the targeted population to all people in risk areas (rather than targeting only pregnant women children under the age of
five), and the expiring of ITNs older than 4 years. ITNs to be distributed in 2010 will expire by 2014, and because less ITNs projected to be distributed
in 2014 compared to 2010, a decrease is expected between 2013 and 2014.
doi:10.1371/journal.pone.0017166.g004
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and ACTs can rapidly reduce malaria associated morbidity and
mortality, as has been the case in Zanzibar where a dramatic
decline in malaria-associated morbidity and mortality has led to a
10-fold reduction in child mortality [36].
There are several limitations to the data used in this study.
Countries set targets in relation to their epidemiological reality,
past experience and capability to scale up services. Hence, some
targets may be overambitious while others too conservative. To
date the results achieved have exceeded the targets set in grants.
Future demand might differ from the current levels assumed in this
study, for example due to strengthening of the capacity of Global
Fund-supported programs over time leading to larger proposals
with more ambitious targets. Similarly, international targets may
be updated as new targets are agreed. The analysis uses UNAIDS
projections as of 2007, prior to 2009 WHO and UNAIDS
guidelines of initiating ARV treatment at CD4 below 350, an
earlier stage than recommended prior 2009. This increased the
estimated number of people in need of ARV treatment from 10
million to 15 million. UNAIDS’ 2007 projections partially
accounts for the 2009 guidelines, as they provide 82% coverage
of those identified 3 years before death, which is equivalent to
CD4 count below 350 with WHO’s clinical stage 3 [37]. Finally,
the projection made for 2011 to 2015 are based on data from
current programs, hence the assumption of no increase in funding
levels. While funding might increase or decrease, our aim is to
show the projected output if there is no change in funding.
Notwithstanding these limitations, our analysis provides the
most up-to-date and comprehensive assessment of the program-
matic output of Global Fund-supported programs against
international targets. In doing so, the analysis provides a more
detailed picture on the achievements of the global efforts towards
international targets on infectious diseases, including the 6
th
MDG.
In conclusion, by end of 2010 Global Fund-supported programs
implemented by countries had contributed substantially to interna-
tional targets and will continue to do so to 2015. Universal access by
2010 is currently unlikely, and as demonstrated by this study, at
current levels of financing and proposed scale up, achieving
universal access targets by 2015 will be difficult [38]. To do so
will require countries to set more ambitious performance targets for
the programs they implement, and for donors to provide
commensurate financing to support scaling up of these programs.
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